title: Secukinumab improves the signs and symptoms of moderate-to-severe plaque psoriasis in subjects with involvement of hands and/or feet: subanalysis of a randomized, double-blind, placebo-controlled, phase 2 dose-ranging study.
authors: Faculty of Medicine, Department of Dermatology, University of Iceland, Reykjavik, Iceland.
authors: B
authors: B
authors: Sigurgeirsson
authors: L
authors: L
authors: Kircik
authors: O
authors: O
authors: Nemoto
authors: I
authors: I
authors: Mikazans
authors: S
authors: S
authors: Haemmerle
authors: H J
authors: HJ
authors: Thurston
authors: C
authors: C
authors: Papavassilis
authors: H B
authors: HB
authors: Richards
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D004311:Double-Blind Method; D005528:Foot / Q000473:pathology*; D006225:Hand / Q000473:pathology*; D006801:Humans; D010919:Placebos; D011565:Psoriasis / Q000188:drug therapy*; D012720:Severity of Illness Index
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D010919:Placebos; C555450:secukinumab